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Abstract
Large (>100 kb), rare (<1% in the population) copy number variants (CNVs) have been shown to 
confer risk for schizophrenia (SZ), but the findings for bipolar disorder (BD) are less clear. In a 
new BD sample from the United Kingdom (n = 2591), we have examined the occurrence of CNVs 
and compared this with previously reported samples of 6882 SZ and 8842 control subjects. When 
combined with previous data, we find evidence for a contribution to BD for three SZ-associated 
CNV loci: duplications at 1q21.1 (P = 0.022), deletions at 3q29 (P = 0.03) and duplications at 
16p11.2 (P = 2.3 × 10−4). The latter survives multiple-testing correction for the number of 
recurrent large CNV loci in the genome. Genes in 20 regions (total of 55 genes) were enriched for 
rare exonic CNVs among BD cases, but none of these survives correction for multiple testing. 
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Finally, our data provide strong support for the hypothesis of a lesser contribution of very large 
(>500 kb) CNVs in BD compared with SZ, most notably for deletions >1 Mb (P = 9 × 10−4).
INTRODUCTION
There is strong evidence for a substantial genetic contribution to risk for both bipolar 
disorder (BD) and schizophrenia (SZ).1 Recent studies have provided evidence that while 
some alleles confer a specific susceptibility to either BD or SZ, others confer susceptibility 
to both disorders.2 Large-scale genome-wide association studies have identified common 
variants (minor allele frequency >0.01) that increase risk of both BD and SZ at CACNA1C, 
ANK3, ITIH3-ITIH4, ZNF804A and NCAN.3–8 Polygenic risk score analyses have also 
shown that large numbers of alleles that are yet to be identified at genome-wide significance 
are over-represented in SZ cases and are also over-represented in cases of BD.9
Copy number variants (CNVs) are structural genomic variations that are >1 kb in size and 
occur in the form of deletions, duplications, insertions and inversions (reviewed in Malhotra 
and Sebat10). Large, rare CNVs (>100 kb in size and present in <1% of individuals) increase 
risk for SZ and other neurodevelopmental disorders including autism spectrum disorders, 
intellectual disability, attention deficit hyperactivity disorder, developmental delay and 
epilepsy.10–14 In a recent study, we showed that 11 CNV loci are significantly associated 
with SZ and four more loci are potentially implicated.15 Overall, 2.5% of individuals with 
SZ carry at least one of these 15 CNVs, compared with 0.9% of controls.15 CNVs have been 
less well studied in BD; the evidence for their involvement in typical forms of the disorder is 
less clear-cut than in SZ.2 Studies in general have not found a significant increase in the rate 
of rare CNVs in individuals with BD compared with controls.16–19 However, it has been 
reported that singleton deletions over 100 kb in length are more frequent in BD cases,17,18 
that an increased rate of CNVs occurs in early-onset BD cases,20 that the frequency of de 
novo CNVs are significantly more frequent in BD cases (with an onset below 18 years of 
age) than controls21 and that the rate of de novo CNVs in BD are intermediate between SZ 
and controls.22 We have not observed such excesses in the Wellcome Trust Case Control 
Consortium (WTCCC) BD CNV analysis, and we did note that the overall rate of CNVs 
seen in BD cases was less than that found in individuals with SZ16 and significantly lower 
than in a reference group with other non-psychiatric disorders.23
In a recent review, Malhotra and Sebat10 reported the rate for CNVs at specific loci that have 
received the strongest support for a variety of disorders (intellectual disability, 
developmental delay, autism spectrum disorder, SZ, and BD and recurrent depression) by 
combining all available data. The CNV occurrence at each locus was reported for BD and 
recurrent depression combined, and suggested an increase of CNVs at four loci: deletions at 
3q29 and 22q11.21, and duplications at 1q21.1 and 16p11.2. The incidence of CNVs at these 
loci for just BD was not reported separately.
In this study, we examined CNVs in a new United Kingdom BD data set (n = 2591), the 
Bipolar Disorder Research Network sample (www.BDRN.org). This sample is independent 
of the WTCCC data set we previously reported.16,23 We performed three types of analysis of 
rare CNVs (<1% of the population): (1) we compared the rate of CNVs in BD vs controls at 
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15 loci that received support for association with SZ, using all available large data sets.15,24 
(2) We examined each gene across the genome for exon-disrupting CNVs in BD compared 
with controls, using a size cutoff of 10 kb. (3) We compared the burden of very large CNVs 
(>500 kb in size) in BD with that in a large SZ data set from the United Kingdom 
(CLOZUK and CardiffCOGs, n = 6882) and with publicly available data from control 
individuals typed on similar arrays (n = 8842).24
MATERIALS AND METHODS
Bipolar disorder cases
The BD sample is a new collection called the Bipolar Disorder Research Network sample 
(www.BDRN.org), recruited in collaboration with the Stanley Center for Psychiatric 
Research at the Broad Institute of MIT and Harvard. All participants were unrelated, white 
European, living in the British Isles. The protocols and procedures were approved by the 
relevant ethics review panels where patients were recruited. The individuals were recruited if 
they suffered with a major mood disorder in which clinically significant episodes of elevated 
mood had occurred. Bipolar cases were excluded if they had experienced mood or psychotic 
illness only as a result of alcohol or substance dependence or medical illness or medication; 
or were biologically related to another study participant. The following methodology was 
used for assessment of bipolar cases: a semi-structured lifetime ever psychiatric interview 
(Schedules for Clinical Assessment in Neuropsychiatry),25 followed by clinical ratings and a 
best-estimate lifetime diagnosis according to the Research Diagnostic Criteria.26 In cases 
where there was doubt as to the best-estimate lifetime diagnosis, diagnostic and clinical 
ratings were made by at least two members of the research team blind to each other’s 
ratings.
The BD cases consisted of 2637 individuals of which 30.8% were male. The mean age of 
recruitment was 46 years (s.d. = 12), with a mean age at first impairment due to BD of 28 
years (s.d. = 11). There were 61% bipolar I disorder/mania, 32% bipolar II disorder/
hypomania and 7% schizoaffective disorder, bipolar type.
Schizophrenia cases
For comparison of BD with SZ, we used two UK-based samples that we previously 
described and analysed for CNVs.12,15,24 The CLOZUK SZ cases (n = 6558) consist of 
individuals taking the antipsychotic clozapine. Subjects (71% male) were aged 18–90 years 
with a recorded diagnosis of treatment-resistant SZ according to the clozapine registration 
forms completed by their psychiatrists. The use of these anonymised samples for genetic 
association studies was approved by the local Ethics Committee. The CardiffCOGS (n = 
571) is a sample of clinically diagnosed SZ patients recruited from community, inpatient and 
voluntary sector mental health services in the United Kingdom. Interview with the SCAN 
instrument25 and case-note review was used to arrive at a best-estimate lifetime diagnosis 
according to DSM-IV criteria.27
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Controls
The control data sets comprised the same sample described in Rees et al.24 in a study of SZ, 
we did not include WTCCC1 controls used in Rees et al.,24 as they have been previously 
used in our WTCCC BD CNV analysis.16 The remaining controls (before quality control 
(QC) filtering) from Rees et al.24 were participants in a smoking cessation study from the 
United States (n = 1491), individuals from the United States who took part in a study of 
melanoma (n = 3102, ~ 2/3 individuals were affected with melanoma), individuals from 
Germany who were participants in a refractive error study (KORA study) (n = 1869) and 
WTCCC2 controls (National Blood Donors cohort: n = 1392 and the 1958 British birth 
cohort: n = 1521). These data sets were chosen because they had been genotyped with 
Illumina (San Diego, CA, USA) arrays that have a high probe overlap with the arrays used to 
genotype the BD cases in the current study. Full details of these samples are available in the 
Supplementary Material. A total of 93.5% of controls were of European descent.
Genotyping and QC filtering
Details of the arrays used for genotyping the data sets are available in the Supplementary 
Material; Supplementary Table S1. The steps for genotyping and QC filtering for the BD 
cases were performed as described in the previously reported SZ sample.15 To ensure that 
the CNV calling was comparable across the different arrays, only probes that were present 
on all arrays were analysed, resulting in a total of 520 766 probes. In addition, to avoid batch 
effects, raw intensity files from each BD, SZ and control data set were analysed 
independently.
The Illumina GenomeStudio software (v2011.1) was used to process the raw intensity data, 
generating Log R Ratios and B-allele frequencies. BD samples were excluded if any of the 
following QC statistics constituted an outlier within their source data set: Log R ratios s.d., 
B-allele frequency drift, wave factor and total number of CNVs. Out of the 2637 BD 
samples with array data, 46 were excluded due to (i) poor QC, (ii) duplicates or related 
(piHat>0.1) individuals of this or previous BD studies by identity by descent and (iii) 
incorrect gender. The numbers and the ethnicities of these subjects are listed in 
Supplementary Material; Supplementary Table S2. The final numbers after exclusions for 
QC and duplicates were 2591 BD cases, 6882 SZ cases and 8842 controls. These samples 
were used for the comparisons between SZ and BD, and for the identification of new loci, 
whereas larger, publicly available data sets were used for the analysis of the 15 SZ-
associated loci.
CNVs went through QC steps described in more detail in the Supplementary Methods. 
Briefly, CNVs were included if their frequency was <1% (applied using PLINK28). 
Subsequently, CNVs were further validated by applying a median Z-score outlier method of 
validation.29 Different size cutoffs were used for the different types of analysis, as detailed 
below.
Statistical analysis
The rates of CNVs at specific loci for BD and controls were compared using Fisher’s exact 
test (two tailed). In order to determine genome-wide significance, we followed a previous 
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practice by employing a Bonferroni correction for multiple testing of recurrent CNVs that 
are flanked by segmental duplications.11,15,24,30 The resulting P-value threshold of 4.1 × 
10−4 is based on 120 genomic regions that are prone to recurrent CNVs (P = 0.05/120). 
When examining associations with CNVs at individual genes, accounting for testing ~ 20 
000 genes, we employed a gene-wide association threshold of P<2.5 × 10−6.
The burden analysis of very large, rare CNVs was performed with PLINK28 using 10 000 
permutations. The analysis was stratified by CNV size (500 kb–1 Mb and >1 Mb), testing 
deletions and duplications separately. To identify novel loci a gene-based approach was 
used.24 Each gene in the genome was examined for exon-disrupting CNVs using hg19 
reference sequence gene coordinates (UCSC genome browser and includes non-coding 
RNAs). Deletions and duplications >10 kb were counted and analysed separately, and 
significance levels were generated using Fisher’s exact test (two tailed) comparing the 
incidence in BD cases against controls. Potential regions were excluded if manual inspection 
of Z-scores, Log R ratios and B-allele frequency traces suggested that they were 
unreliable.24,29
Power calculations were performed using the online open source genetic power calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/).31 Frequencies and odd ratios for BD were 
taken from the review by Malhotra and Sebat.10
RESULTS
Previously implicated SZ loci
We examined the rates of CNVs in BD cases and control groups at 15 loci previously 
implicated in SZ.15 The CNV rates were based on the following data sets: (i) BDRN cases in 
this current study, (ii) data from a meta-analysis by Malhotra and Sebat10 for BD cases (after 
excluding those with major depression), (iii) BD cases from the study by Bergen et al.,18 in a 
Swedish population and (iv) samples used in our previous CNV study16 using the BD cases 
from the WTCCC1 for loci that were not included in the Malhotra and Sebat10 study. In 
some instances, one or more of these four sources did not provide data for a particular CNV 
locus. A full description of which sources contributed to each of the 15 CNVs analysed is 
provided in the Supplementary Material; Supplementary Table S3. The CNV occurrence in 
controls are taken from Rees et al.,15 which reports the data from large combined control 
data sets ranging from 27 045 to 81 821 samples in total.
The rates of CNVs in all reported large BD data sets and control groups at the 15 loci are 
presented in Table 1. For 3 of the 15 CNVs, we noted nominally significantly higher rates in 
BD cases than in controls (without correction for multiple testing). The strongest evidence 
for association was obtained for duplications at 16p11.2, which were increased in BD cases 
(0.13%) compared with controls (0.03%) with a combined P-value of 2.3 × 10−4, surpassing 
our genome-wide significance threshold for this type of CNV (see Methods) and 
strengthening the evidence from previous studies. Supplementary Figures S1 and S2 indicate 
the positions of the duplications, Log R ratios and B-allele frequency traces using Illumina 
GenomeStudio in the three BD samples across 16p11.2. The other nominally significant loci 
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were duplications at 1q21.1 and deletions at 3q29 (P-values, 0.022 and 0.03, respectively), 
which do not survive any multiple-testing correction.
Analysis of novel CNV loci
Genes across the genome were examined for CNVs that disrupted exons in the BD BDRN 
sample set (n = 2591) and control samples (n = 8842), excluding the 15 previously 
implicated SZ loci reported in Table 1. A total of 55 genes mapping to 20 distinct genomic 
regions were enriched among our BD cases with nominal levels of significance (two-sided 
Fisher’s exact test, P-value<0.05) (Supplementary Table S4), but no gene reached the 
genome-wide association threshold for the 20 000 genes examined (P<2.5 × 10−6). Within 
our data set, the strongest evidence for association was for duplications at ATF7IP2 
(encoding activating transcription factor 7—interacting protein 2) located at 16p13.2–
p13.13, which was found in eight BD cases (0.31%) and in four controls (0.045%, two-sided 
Fisher’s exact test, P = 1.4 × 10−3). The gene, GRIN2A encoding glutamate receptor, 
ionotropic, N-methyl-D-aspartate, subunit 2A, lies downstream of ATF7IP2. Its first exon is 
disrupted in seven BD cases and five controls (0.27% BD vs 0.057% controls, two-sided 
Fisher’s exact test, P = 8.1 × 10−3). Supplementary Figure S3 indicates the positions of the 
duplications in all samples across ATF7IP2 and GRIN2A.
In addition, there is evidence of association for duplications at the gene CGNL1 (cingulin-
like 1) at 15q21.3, intersected in 13 BD cases (0.50%) and 19 controls (0.21%), two-sided 
Fisher’s exact test, P = 0.021. A significant excess of duplications at this gene have been 
previously observed in SZ.24 Supplementary Figure S4 indicates the positions of the 
duplications in the cases and controls across CGNL1.
CNV burden analysis
We compared the rate of CNVs in BD with those in SZ cases and in controls. The burden 
analyses were performed only on the BD, SZ and control data sets where we had access to 
raw data and that were genotyped with Illumina arrays (BD: n = 2591; SZ: n = 6882; 
controls: n = 8842), as described in the Materials and methods section. As CNV burden 
analysis is highly susceptible to technical bias, we limited it to the largest class of CNVs, 
those >500 kb, which should be called reliably on all arrays used in different data sets. BD 
cases were not significantly different from controls in any comparison (Table 2). SZ cases 
had more deletions >1 Mb compared with BD cases (two sided, P = 9 × 10−4). Duplications 
in the size range of 500 kb–1 Mb were also more common in SZ compared with BD cases 
(two sided, P = 0.045). As this excess could be due to the already implicated 15 SZ CNV 
loci (listed in Table 1), the analysis was repeated after removing CNVs in these loci. Neither 
of the comparisons remained even nominally significant, suggesting that a large part (but not 
all) of the excess in SZ is due to CNVs at those known loci: (deletions >1 Mb, SZ 0.87%, 
BD 0.54%, P = 0.12; duplications, 500–1 Mb, SZ 5.1%, BD 4.3%, P = 0.12).
DISCUSSION
It is well documented that specific CNVs contribute to the susceptibility of SZ, however, the 
involvement of CNVs in BD is less compelling. In a new independent BD sample, we have 
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studied rare, large CNVs and analysed their frequencies in this sample and in previously 
reported BD, control and SZ data sets.10,15,16,18,24 The incidence of CNVs in this new BD 
data set had not been previously reported, although a large proportion of the sample has been 
used for genome-wide association studies.3 The SZ, BD and control samples were 
genotyped on a variety of Illumina arrays, but only probes present on all arrays were 
analysed (n = 520 766). In addition, for all data sets (SZ, BD and controls) the methodology 
used was identical for CNV calling and statistical analysis.
Combining the BDRN BD data with recently reported CNV analyses10,15,16,18,24 provided 
support for three of the 15 previously implicated CNVs in SZ. Two of the loci, 1q21.1 
duplication and 3q29 deletion were nominally significant with a two-sided P-value of 0.022 
and 0.03, respectively, and these results do not survive correction for multiple testing. The 
strongest evidence was for duplications at 16p11.2 (two-sided P-value = 2.3 × 10−4), which 
survives correction for the number of potential recurrent CNV loci in the genome (P-
value<4.2 × 10−4) and is the most significant BD-associated CNV to date. The locus was 
implicated in BD before10,32 (P = 8 × 10−4 for BD and major depression combined,10 P = 
0.017 for BD32), but the current study raises the statistical support to above a level that is 
regarded as genome-wide significant for this type of CNV locus. Additional phenotypic 
details for the three carriers of 16p11.2 duplication are available in Supplementary 
Information. All three individuals had a DSM-IV rating of bipolar I disorder, and had 
episodes of depression as well. There was nothing unusual in their recorded presentations 
and at least two of them appeared to have no cognitive deficits, attaining O- or A-levels at 
school. The locus 16p11.2 has been also previously implicated in neuropsychiatric disorders 
via a genome-wide association study of mixed SZ and BD (psychosis) phenotypes, which 
revealed a novel variant at 16p11.2 showing genome-wide association for rs4583255 (P-
value 6.6 × 10−11, odds ratio = 1.08) located in the 593-kb CNV duplication region33 within 
the gene TAOK2. A significant excess of a combination of micro-deletions and duplications 
at 16p11.2 has also been reported in major depressive disorder in a German sample.34
Our BD discovery sample consists of 2591 cases and 8842 controls, and has a power of 74 
and 80% with an a of 0.05 to detect associations with duplications at 1q21.1 and 16p11.2, 
respectively. However, for the associations with the 15 SZ loci we used all available data 
sets, increasing the numbers of BD cases to ~ 4000–9000 and the numbers of controls to 
those that provided the definitive findings in SZ. Although the BD case numbers are still 
smaller than for SZ, it is clear (Table 1) that for some of the loci the frequencies in BD are 
very similar to those of controls, suggesting that this is not a power problem but more likely 
a genuine difference between SZ and BD.
We provide a list of the top hits for duplications and deletions at 55 genes that are more 
frequently affected in BD cases compared with controls (Supplementary Table S4). The 
significance for any of these genes does not survive a Bonferroni correction for multiple 
testing of 20 000 genes separately for deletions and duplications (P<2.5 × 10−6). The 
strongest evidence for association was for duplications at ATF7IP2. GRIN2A, a glutamate 
receptor, lies downstream of ATF7IP2, and although less significantly associated with BD, 
functionally it is the better candidate, as glutamate signalling pathways are thought to be 
involved in genetic predisposition to BD.35 In addition, GRIN2A is associated with SZ, 
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meeting genome-wide significance.36 At the gene CGNL1 (cingulin-like 1), there is overlap 
with our current BD data and SZ. Here, we report an excess of duplications in BD cases 
compared with controls in this gene, for which we also note an excess of duplications in SZ 
cases compared with controls.24 However, we note that the control samples used in the 
current BD study are not independent of those used in the previous SZ study. Replication in 
independent studies of both cases and controls is required to confirm the involvement of any 
of these loci with BD.
CNV burden analyses have shown an increased burden of large, rare CNVs in SZ: we 
reported a 2.5% higher rate of CNVs larger than 500 kb in SZ compared with controls.24 
Using the same SZ data set to compare the burden of CNVs in BD revealed a significant 
difference between SZ and BD with respect to large, rare CNVs, in particular deletions. 
However, this excess was partially explained by the 15 loci already implicated in SZ. When 
comparing BD and control samples, we saw no significant difference in CNV burden for any 
of the CNV sizes examined. Both observations support our previous findings examining 
CNVs in BD cases and controls genotyped as part of the WTCCC study.16 These findings do 
not, however, exclude the involvement of CNVs in the susceptibility of BD at some specific 
loci. However, very large CNVs appear to contribute less to BD than to SZ.16,32 Larger 
structural variants often appear to predispose to persistent, wide-ranging brain dysfunction, 
including those that affect cognitive and personality development.2,23,37
In summary, we have performed CNV analysis in a large independent BD data set and 
compared the CNV burden with both SZ and controls. Our data confirms previous findings, 
suggesting that there is a significant difference between SZ and BD in terms of CNV 
occurrence, in particular for large deletions >1 Mb. We do not rule out the possibility of 
CNV involvement in the susceptibility of BD at specific loci. In fact, we observe an increase 
of duplications at 16p11.2 and 1q21.1, deletions at 3q29 and the potential involvement of 
additional CNVs, all of which require replication.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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